## ICUI: ICU Medical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.1% below STRENGTH zone (4.0-10.0%); PEG 1.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (50% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($136.87)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.3% (-1.2%)
- Vanguard Group Inc: 10.6% (-1.3%)
- Janus Henderson Grou: 10.0% (+0.1%)
- Fuller & Thaler Asse: 5.6% (-0.3%)
- JPMORGAN CHASE & CO: 5.5% (+78.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.70 elevated, pricing in significant growth expectations. Forward P/E 18.1x stretched relative to 6% growth. Balance sheet: strong liquidity (2.5x). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.6B |
| Beta | 0.83 |
| 52W Range | $107.00 - $175.51 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.70 |
| Forward P/E | 18.1 |
| Current P/E | 19.1 |
| YoY Growth | 6.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 5.1pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.73), momentum weakening. RSI neutral at 51. Volume at 50% of 20MA suggests lack of conviction. OFD pattern: -F0L (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.09% (CS: 30) | Neutral |
| RSI_14 | 51.3 | Neutral |
| MACD Histogram | -0.73 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.049x | Above |
| vs SMA200 | 1.089x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $144.63
- **Stop Loss:** $136.87 (5.4% risk)
- **Target:** $152.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 170
- **Position Value:** $24,587.10
- **Portfolio %:** 24.59%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-26 (Est: $1.69)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $2.03 | +41.6% |
| 2025Q2 | $1.50 | $2.10 | +40.0% |
| 2025Q1 | $1.28 | $1.72 | +34.4% |
| 2024Q4 | $1.48 | $2.11 | +42.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*